Things just get “curiouser and curiouser.” Alice in Wonderland , Lewis Carroll Alice's remark as she visited wonderland is quite applicable to the rapidly changing medical knowledge base. The more we know, the more questions that occur, and this “quest for truth” is daunting. This is a daily element of clinical decision-making in a busy practice, face to face with patients and parents. This is particularly true when addressing the area of drug therapy for attention-deficit disorder with or without hyperactivity [ADD(H)]. Over the past 2 years, there has been a lot of information on this topic. Parents are aware of the emotionally charged aspects of ADD(H) therapy through the rapid access of information from all forms of media. They are raising important questions regarding the safety of use of the stimulant class of drugs for treating ADD(H). The recent concern of sudden cardiac death in patients who are taking these drugs is certainly worth evaluation. What follows is a brief synopsis of the clinically relevant, best evidence-based aspects of this issue. Sudden cardiac death occurs at an estimated rate of 1.3 per 100000 patient-years in the pediatric population.1 It is often assumed under conditions of an unexplained, unexpected death in an otherwise presumed healthy person. … Address correspondence to Matthew Knight, MD, OSFMG Morton Pediatrics, 435 Maxine Dr, Morton, IL 61550. E-mail: meknight50{at}yahoo.com
Read full abstract